SL1009 (sodium dichloroacetate)

Name: SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Pathophysiology
Published: 2026-09-14T15:39:06-04:00

Pyruvate dehydrogenase complex deficiency

Manufacturer: Saol Therapeutics
Regulatory submission: NDA resubmitted June 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

2 evidence topics · 2 sources

Pathophysiology and disease consequences

“chronic energy deficit leading to lactic acidosis, profound developmental problems, and early childhood death.” (opens the source at this quote in a new tab)

Impaired pyruvate metabolism

“pyruvate cannot be metabolized into acetyl‐CoA, resulting in a mitochondrial disorder with lactic acidosis, seizures, and severe encephalopathy.” (opens the source at this quote in a new tab)